Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Length of hospital stay · preterm infants at risk for apnea
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Length of hospital stay · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Duration of attacks per day (minutes) · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
IV antibiotics: number of days on IV antibiotics · adolescents and adults with cystic fibrosis
Digital technology showed no clear difference in IV antibiotics: number of days on IV antibiotics compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Finding 7. Patients regarded in‐person home‐based rehabilitation and telerehabilitation services as convenient and less disruptive of everyday activities.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review